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Comparing the Hub-and-Spoke Model Practices of the LifeLines
Study in the Netherlands and the H3Africa Initiative
Marcel Bruinenberg,1 Martin Frey,2 Mary Napier,3 and Annette Summers4
Biobank sample storage is critical in population health and epidemiology studies. Biobanks bridge two very
different worlds: they connect to the participants and patients at an individual level, but they also aggregate
information and represent the cutting edge of scientific discovery. In this brief report, we describe how the
LifeLines study in the Netherlands manages its resources for communication and services, and how it can serve
as a model for the Human Heredity and Health in Africa Initiative (H3Africa Initiative).
Introduction
Modern biobanks are important platforms for in-tegrating genomic technologies, donors, and the
medical sciences. Under the hub-and-spoke model, samples
are collected in multiple clinics/hospitals and then sent to
the central ‘‘hub’’ for final processing, storage, and subse-
quent retrieval for experimental analysis.1 Central to the
success of any biobank is a scientific infrastructure to ensure
that each step, from sample acquisition through reporting
study results, meets or exceeds the high quality standards of
the international community.
Scientific researchers depend on biobanks to supply well-
annotated, high-quality samples that are collected within
appropriate ethical parameters, with an infallible chain of
custody. As many large population studies exceed 100,000
participants and often involve time-course sampling, the
numbers of samples can quickly run into the millions.
Biobanks therefore need to manage their resources effi-
ciently to keep up with demand.2,3
For biobanks to act as service hubs, they need to have an
auditable system to collect, organize, and store samples, and
a way to communicate with each other. All samples typi-
cally have a Globally Unique Identifier (GUID), and a list of
common data elements (CDE) to ensure that relevant data is
collected. The CDE list is used as metadata to standardize
definitions between software systems, which enables data to
be used across multiple studies.
Standardization also facilitates data collection because it
allows for more robust study analytics, and some elements
of data collection can be automated.4,5 For example, CDE
can also be used to establish a back-end, web-based inter-
face that links to the biospecimen database, where certain
elements can be included in the downstream sample pro-
cessing workflow software.5 Larger biobanking initiatives
should consider advanced automation and information
technology (IT) infrastructures to track and process samples.
Instrumentation and sample processing automation are de-
ployed at varying levels throughout the hub-and-spoke service
network of a biobank. For example, participants are assigned
unique identifiers, and a software application programming
interface (API) is organized to include relevant data elements,
facilitating automated sample registration linking back to the
software and IT systems of the regional spokes and hubs.5,6
Discussion
The LifeLines Study
The LifeLines study (https://www.lifelines.nl/) is a popu-
lation-based, observational follow-up study that seeks to
identify universal risk factors and risk-factor modifiers for
multi-factorial disease using 165,000 participants in the
Netherlands.6 This life-course epidemiology study will ex-
amine healthy aging and prevalent diseases such as cardio-
vascular disease, diabetes, asthma/COPD (chronic obstructive
pulmonary disease), and depression.7
The LifeLines study is a prime example of how modern
technology is facilitating audit trails and enhancing privacy
standards during sample collection, storage, and analysis.
These standards are implemented by the biobank to meet
best practices set by the International Society for Biological
and Environmental Repositories (ISBER).
The LifeLines study has established 10 collection centers
throughout the three northern provinces of the Netherlands.
Participants are recruited by establishing collaborations with
general practitioners, and assigned a unique identifier to
track interactions with that specific person.6
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Additional participant information is collected with an-
nual questionnaires, and by linking to general practitioners
and pharmacy registries. Blood and urine are collected every
5 years, and all information is anonymized and included in
the study’s dataset. The study will use this data to assess
how disease risks—genetic heredity, time-dependent or
environmental—can impact health outcomes.7
The clinical Trial Coordination Center (TCC) at the
University Medical Center Groningen (UMCG) curates the
data for the LifeLines study.8 The TCC developed electronic
case form reports that incorporate CDEs and unique iden-
tifiers so the information can be ported to multiple software
programs and databases. This enables project staff to enter
data and access it from various locations throughout the
Netherlands.
The linking and tracking of data begins as soon as the
sample is collected and is performed at the database level
with a complete audit trail. The laboratory information
management system (LIMS) registers the sample for trans-
port and records the temperature conditions during the
sample’s journey.
The LifeLines study processes about 2000 primary tubes
daily, resulting in more than 8000 aliquots for storage.9
Sample processing begins a few hours after samples are
retrieved from the collection sites and transported to the
central processing laboratory. The majority of samples go
through an automated processing step for storage, which is
performed by liquid handlers with complete LIMS tracking
and tracing.
Liquid handling machines read the unique sample iden-
tifier at intake and keep a complete sample history in the
instrument log file. This information is used to update the
LIMS with actions involving the sample, such as generating
aliquots into new tubes. All samples are processed and
stored within 10 hours of collection.
To store its collection, the LifeLines study chose the
BiOS system from Hamilton Storage Technologies, an
innovative automated system designed for ultra-low-
temperature storage of sensitive biological samples. The
system ensures the integrity of up to 10 million sample tubes
at temperatures as low as - 80C. The LifeLines study has
already collected approximately 5 million samples and plans
to collect more than 8 million by 2017.6
Researchers who want to use the data and samples in the
LifeLines study submit a proposal that is screened by an
expert committee. If deemed scientifically significant, data
and samples are released to the researcher by the LifeLines
study.
The ‘‘hub’’ of the LifeLines study is located in a historic
building in the center of Groningen near the UMCG hos-
pital. The building’s limited floor space did not allow for
storing millions of samples, so they are kept several miles
away, in an industrial park that underwent a thorough risk
assessment. The need to transport the samples from the
LifeLines laboratory to the new off-site, state-of-the-art
automated storage facility created an additional challenge,
and Hamilton Storage Technologies designed custom-made
transportation cassettes for this purpose.9
After processing, the samples are placed into the trans-
portation cassettes, which are put into ultra-low-temperature
freezers and transported by truck to the new storage facility.
Once there, the freezers are placed in a temperature-
controlled, low-humidity room adjacent to the BiOS sys-
tem.9 The transportation cassettes can be placed directly in
the I/O module of the BiOS for immediate processing into
the storage chests. This ensures the sample is secure and
stays viable for many years.
The H3Africa Initiative
The H3Africa Initiative (http://www.h3africa.org/) aims
to facilitate a contemporary research approach to the study
of genomics and environmental determinants of common
diseases with the goal of improving the health of African
populations. The goal of the H3Africa biobanking initiative
is to build a fully functioning biorepository for African
countries that can receive and distribute samples utilizing
international standards.10 The initiative is expected to lead
to the distribution of biological research samples to at least
15 countries in Africa.
This H3Africa pilot biobanking initiative is directed by
Professor Akin Abayomi of South Africa’s National Health
Laboratory Services (Tygerberg Hospital business unit) and
the Faculty of Medicine of Stellenbosch University in col-
laboration with the South African National Bioinformatics
Institute (SANBI), Rutgers University (RUCDR), IFA-
SEMB, and the Scripps Research Institute for Regenerative
Medicine.11
The H3Africa biobanking team plans to employ ISBER
best practices to catalog the genetic diversity of African
populations and, in turn, contribute to the knowledge of
human diversity and disease biology.12 Researchers believe
that discoveries from the genetically diverse population of
Africa will help identify genetic risk factors that might be
harder to identify in more genetically homogenous popula-
tions.12 Studies that are being explored range from case-
control, genome-wide association studies in rheumatic heart
disease to pharmacogenomics and pharmacokinetic multi-
center and multi-country trials.11,13
The H3Africa Initiative has to cover a diversity of heri-
tages, wide-ranging climates, and vast distances. In 2012,
the bioinformatics networks in Africa could be described as
a mixture of point-to-point and hub-and-spoke networks
(Fig. 1).14 To ensure that the H3Africa Initiative has the IT
infrastructure to support its study, Nicola Mulder, principal
investigator at the University of Cape Town in South Africa,
is performing a needs assessment. Dr. Mulder is charged
with building a communication infrastructure project to
enhance existing nodes across the African continent and
provide a pan-African bioinformatics network.15
The H3ABioNet program (http://www.h3africa.org/
projects/16-projects/64-h3abionet-a-sustainable-african-
bioinformatics-network-for-h3africa), which is creating a
sustainable Bioinformatics Network to support H3Africa
researchers through the development of bioinformatics ca-
pacity on the continent, aims to have 20 nodes, with nine
full nodes, six associate nodes, and five development
nodes.15 The network will provide infrastructure and hard-
ware, human resources, tools, training, and computational
solutions for genomic and population-based research, as
well as communications among African researchers and
other interested parties. This will enable samples to be fol-
lowed throughout the network, from collection to storage
and analysis, as often as needed.
The initial grants for biobanks and investigators for the
H3Africa Initiative supported pilot projects to understand
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the needs, test capabilities, and assess strengths as well as
areas in need of better infrastructure.16 Pilot Phase I bior-
epository projects were funded at the Institute for Human
Virology (IHV) in Nigeria (partnered with the Coriell In-
stitute for Medical Research) and Stellenbosch University in
South Africa (partnered with the South African National
Biodiversity Institute and the Scripps Institute for Re-
generative Medicine).17
The principal investigators at these institutions have
participated in a variety of international and African pro-
jects, giving them unique insight into the challenges of es-
tablishing biorepositories in Africa. For example, the IHV
was formed in 2004 as part of the US President’s Emer-
gency Plan for AIDS Relief (PEPFAR). The IHV also par-
ticipates in studies for the Global Fund to Fight AIDS,
Tuberculosis and Malaria. It supports treatment sites com-
prised of primary, secondary, and tertiary health centers in
28 states within Nigeria.18 It is expected that these pilot
studies will lead to a 5-year grant to establish biobanks
equipped with automated liquid handlers and automated
storage units.
Cultural differences between African countries and in-
consistent levels of infrastructure within a country com-
pound the difficulties of conducting a study to international
standards in Africa. This makes the hub-and-spoke model
important to deploy, but it also makes the study vulnerable
to breaks within the system between points. Differences
begin at obtaining informed consent from potential partici-
pants and continue through collecting the sample and
transporting it back to the study site. For example, in
western societies, an individual will give their consent to
participate, while in some communities in Africa the tribal
leader may have the authority to grant consent for multiple
participants. Language barriers are also more pronounced in
Africa; Nigeria, for instance, has 11 official languages and
510 living tribal languages.
To overcome these challenges, the H3Africa Initiative is
employing local researchers and staff who speak the lan-
guages, deploying motorcycles to remote villages to collect
FIG. 1. H3ABioNet Map, participating
African Institutions. Map of the 32 institu-
tions supporting the H3Africa Initiative in
Africa (accessed online December, 2013).
H3ABioNet has two US institutions, the
University of Illinois and Harvard School of
Public Health. An interactive map is found
online at: http://www.h3abionet.org/about/
map.
FIG. 2. Current status of the biobanking components of
the LifeLines study and the H3Africa Initiative. Illustration
of the six different phases of development of a biobank
(modified from Biobanking Solutions (http://www.bio
bankingsolutions.ac.uk/) and P3G (http://p3g.org/).
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samples, and exploring how best to keep samples viable in
ambient conditions, among other practices.19 One such re-
searcher is Dr. Alash’le Abimiku of the IHV in Nigeria. He
will assess current practices to identify strengths and
weaknesses, upgrade repository practices and infrastructure
to meet the needs of the H3Africa Initiative, advocate for
host government and community support, and conduct im-
plementation and quality control tests that will allow scale-
up by the end of the pilot period.18
Conclusion
The LifeLines study and the H3Africa Initiative bridge
vastly different cultures and technological infrastructure.
While the LifeLines study has collected more than 5 million
samples, the H3Africa Initiative is still setting up the bio-
banks and building infrastructure and capabilities (Fig. 2).
The LifeLines study illustrates several key components of
a successful biobanking effort such as careful resource
management, thoughtful IT infrastructure design supporting
the communication needs, and design of specialized equip-
ment when necessary. The ‘‘hub-and-spoke-model,’’ which
connects the hub to its collaborators, may serve as a useful
model for the H3Africa Initiative, although it may be nec-
essary to implement this model slightly differently. The hub-
and-spoke model is very effective in gaining efficiencies and
conserving resources, but it is vulnerable to disruption when
one route goes down. In some cases in Africa, overcoming
logistical issues between routes may be untenable due to lack
of infrastructure. As such, an approach that incorporates
relevant parts of other models may be the most efficient.
The largest challenge for the H3Africa Initiative is finding
trained scientists and technicians who can manage the
complexities of the study and commit to following proce-
dures even in the most challenging circumstances. The
H3Africa Initiative has recruited a consortium of high-level
researchers from renowned institutions both in Africa and
from other countries. As the investigators gain experience
with state-of-the-art instrumentation and automation and the
latest in IT infrastructure, they are sharing this knowledge
with local researchers and employing local talent.
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